Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • ID: 4027273
  • Report
  • Region: Global
  • 65 Pages
  • GBI Research
1 of 4
Hepatitis C has a High Global Prevalence, with the Number of People Living with the Disease Estimated at 130-170 Million Worldwide
Hepatitis C market has witnessed a historically rare market penetration in terms of the breadth and quality of several strongly innovative and very competitive new products, known as direct-acting antivirals (DAA). The latest DAA combination therapies, such as Harvoni, Zepatier and Epclusa, have been shown to clear hepatitis C virus (HCV) infection in over 90% of treated individuals, demonstrating superior efficacy and tolerability compared with interferon-based therapy and older-generation DAAs.

Hepatitis C is a blood-borne viral infection characterized by chronic inflammation of the liver. Although patients may be asymptomatic for a number of years or decades, chronic HCV infection can lead to liver fibrosis (formation of scar tissue) and ultimately liver cirrhosis, in which permanent fibrotic scar tissue replaces healthy liver cells. In severe cases, cirrhosis may lead to liver failure and death. In addition, hepatitis C patients are at an increased risk of developing liver cancer.

Despite the entry of new therapies, there is a subgroup of patients that do not respond to current treatments, or relapse. In addition, HCV resistance to DAAs may also be a cause for concern, as the development of selection pressure by the host immune system in combination with DAA therapy may lead to outgrowth of resistant viruses. As such, the rationale for investment in first-in-class innovation remains strong.

Recent years have seen a revolution in hepatitis C therapeutic development, and the treatment algorithms have rapidly shifted away from interferon-based therapies and towards interferon-free direct-acting antiviral (DAA) combination therapies. Compared with the older treatments, DAA combination therapies have a favorable safety profile and excellent tolerability and efficacy, achieving cure rates of over 90%.

Although a number of highly effective products have entered the market in the last few years, hepatitis C remains a relatively attractive indication for a number of reasons. There is a large patient population that has unmet needs due to being unresponsive or relapsing following treatment. In addition, the high therapy costs of the newer treatments present a major barrier to care.

The report “Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations” allows you to appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.

In depth, it provides the following:
  • Visualize the composition of the hepatitis C market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.
  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to hepatitis C, all first-in-class targets in the hepatitis C pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Unmet Needs Remain in Hepatitis C Market
2.2 Pipeline Dominated by Direct-Acting Antivirals with Small Number of First-in-Class Products
2.3 Diverse Range of Host-Targeting and Direct-Acting Antivirals in First-in-Class Pipeline

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 GBI Research Report Guidance

4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Disease Symptoms
4.3 Epidemiology
4.4 Etiology and Risk Factors
4.5 Pathophysiology
4.6 Disease Progression
4.6.1 Acute Stage
4.6.2 Chronic Stage
4.6.3 End Stage
4.6.4 Factors Affecting Progression
4.7 Co-morbidities and Complications
4.8 Diagnosis
4.9 Treatment Options and Treatment Algorithm
4.9.1 Treatment Options
4.9.2 Treatment Algorithm
4.10 Overview of Marketed Products in Hepatitis C
4.10.1 Molecule Type and Molecular Target Analysis

5 Assessment of Pipeline Product Innovation
5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target
5.2 Comparative Distribution of Programs between the Hepatitis C Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Programs Targeting Novel Molecular Targets

6 Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks in Hepatitis C
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment

7 First-in-Class Target Evaluation
7.1 Viral Targets
7.1.1 Pipeline Programs Targeting HCV P7
7.1.2 Pipeline Programs Targeting HCV Envelope Proteins E1 and E2
7.1.3 Pipeline Programs Targeting HCV NS4B
7.2 Host Targets
7.2.1 Pipeline Programs Targeting MicroRNA
7.2.2 Pipeline Programs Targeting Toll-like Receptor
7.2.3 Pipeline Programs Targeting Claudin
7.2.4 Pipeline Programs Targeting Serine C-Palmitoyltransferase
7.2.5 Pipeline Programs Targeting Type III Phosphatidylinositol 4-Kinase Beta
7.2.6 Pipeline Programs Targeting Caspases

8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals

9 Appendix
9.1 References
9.2 Abbreviations
9.3 Research Methodology
9.4 Secondary Research
9.4.1 Market Analysis
9.4.2 Pipeline Analysis
9.4.3 First-in-Class Matrix Assessment
9.4.4 First-in-Class Target Profiles
9.4.5 Licensing and Co-Development Deals

List of Tables

Table 1: Hepatitis C Therapeutics Market, Risk Factors for Fibrosis Progression, 2016
Table 2: Hepatitis C Therapeutics Market, Global, Characteristics of DAAs, 2016
Table 3: Hepatitis C Therapeutics Market, Global, Categories of Approved DAA Therapies in Hepatitis C, 2016
Table 4: Hepatitis C Therapeutics Market, Global, AASLD/IDSA Hepatitis C Treatment Guidelines, 2016
Table 5: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV P7, 2016
Table 6: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV P7, 2016
Table 7: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV Envelope Protein E1 and E2, 2016
Table 8: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV Envelope Protein E1 and E2, 2016
Table 9: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV Envelope Protein E2, 2016
Table 10: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV Envelope Protein E2, 2016
Table 11: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of HCV NS4B, 2016
Table 12: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting HCV NS4B, 2016
Table 13: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of MicroRNA 122, 2016
Table 14: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting MicroRNA 122, 2016
Table 15: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Toll-like Receptor 3, 2016
Table 16: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Toll-like Receptor 3, 2016
Table 17: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Claudin 1, 2016
Table 18: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Claudin 1, 2016
Table 19: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Serine C-Palmitoyltransferase, 2016
Table 20: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Serine C-Palmitoyltransferase, 2016
Table 21: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Type III Phosphatidylinositol 4-Kinase Beta, 2016
Table 22: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Type III Phosphatidylinositol 4-Kinase Beta, 2016
Table 23: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 1, 2016
Table 24: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 2, 2016
Table 25: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 3, 2016
Table 26: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 5, 2016
Table 27: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 6, 2016
Table 28: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 7, 2016
Table 29: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 8, 2016
Table 30: Hepatitis C Therapeutics Market, Global, Key Features and Pipeline Activity of Caspase 9, 2016
Table 31: Hepatitis C Therapeutics Market, Global, Pipeline Programs Targeting Caspases, 2016
Table 32: Abbreviations

List of Figures

Figure 1: Hepatitis C Therapeutics Market, US, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals, 1987-2014
Figure 2: Hepatitis C Therapeutics Market, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval ($m), 2006-2013
Figure 3: Hepatitis C Therapeutics Market, Major Markets, Hepatitis C Prevalent Population (million), 2015-2022
Figure 4: Hepatitis C Therapeutics Market, Major Markets, Hepatitis C Treatment Rate (‘000), 2015-2022
Figure 5: Hepatitis C Therapeutics Market, HCV Genomic RNA, 2016
Figure 6: Hepatitis C Therapeutics Market, Global, Marketed Products by Molecule Type and Molecular Target, 2016
Figure 7: Hepatitis C Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2016
Figure 8: Hepatitis C Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 9: Hepatitis C Therapeutics Market, Global, Distribution of Molecular Targets Across Pipeline and Marketed Products, 2016
Figure 10: Hepatitis C Therapeutics Market, Global, Distribution of Pipeline First-in-Class and Established Products, 2016
Figure 11: Hepatitis C Therapeutics Market, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Stage of Development (%), 2016
Figure 12: Hepatitis C Therapeutics Market, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Molecular Target (%), 2016
Figure 13: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 1)
Figure 14: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 2)
Figure 15: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 3)
Figure 16: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 4)
Figure 17: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 5)
Figure 18: Hepatitis C Therapeutics Market, Global, Pipeline Products, 2016 (Part 6)
Figure 19: Hepatitis C Therapeutics Market, Global, First-in-Class Molecular Target for Host Factors Matrix Assessment, 2016
Figure 20: Hepatitis C Therapeutics Market, Global, First-in-Class Molecular Target for Viral Proteins Matrix Assessment, 2016
Figure 21: Hepatitis C Therapeutics Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
Figure 22: Hepatitis C Therapeutics Market, Global, Industry-Wide Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2014
Figure 23: Hepatitis C Therapeutics Market, Global, Licensing Deals by Region and Deal Value ($m), 2006-2016
Figure 24: Hepatitis C Therapeutics Market, Global, Disclosed and Undisclosed Licensing Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015
Figure 25: Hepatitis C Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016
Figure 26: Hepatitis C Therapeutics Market, Frequency and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, Global, 2006-2016
Figure 27: Hepatitis C Therapeutics Market, Global, Co-development Deals by Region and Deal Value ($m), 2006-2016
Figure 28: Hepatitis C Therapeutics Market, Global, Disclosed and Undisclosed Co-development Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015
Figure 29: Hepatitis C Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016
Figure 30: Hepatitis C Therapeutics Market, Global, Frequency and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2016
Figure 31: Hepatitis C Therapeutics Market, Global, First-in-Class Programs with No Recorded Prior Deal Involvement, 2016
Figure 32: Hepatitis C Therapeutics Market, Global, First-in-Class Programs with Prior Deal Involvement, 2016

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll